Scope and claims analysis and U.S. patent landscape for U.S. Patent 12,318,374 (solid dispersion with amorphous Formula (I) compound and HPMC-AS water-limited)

Executive summary U.S. Patent 12,318,374 is narrowly anchored to an oral pharmaceutical composition where a Formula (I) compound is in amorphous form and is delivered in a solid dispersion containing hydroxypropyl methyl cellulose acetate succinate (HPMC-AS) with a tightly controlled residual water limit (≤ about 6 wt%, with dependent claim stair-steps down to ≤ about 1 wt%). The claim set you provided is composition-focused and uses water-content ranges as the primary technical differentiator. This construction typically creates a defensible claim boundary around manufacturing control of moisture during solid-dispersion formation and storage rather than around broad formulation ingredients. The practical freedom-to-operate risk depends on whether competitors can (i) avoid HPMC-AS, (ii) avoid amorphous form, or (iii) meet the same water ceiling profiles in the finished solid dispersion.

What is U.S. Patent 12,318,374 scope for oral solid dispersions with amorphous Formula (I) and HPMC-AS water limits?

Core claim architecture

From the claims provided, the patent’s independent/composition backbone is:

Type: “A pharmaceutical composition for orally delivering” (also repeated as “oral delivery”).
Delivery system: solid dispersion.
Active state requirement: the compound represented by Formula (I) is present in amorphous form.
Polymer excipient requirement: hydroxypropyl methyl cellulose acetate succinate.
Finished composition parameter: water present in ≤ about 6 wt% (with dependent ranges).

The dependent claims then narrow the same structure with progressively lower water ceilings:

≤ about 5%
≤ about 4%
≤ about 3.5%
≤ about 3.4%
≤ about 3%
≤ about 2%
≤ about 1%

This yields a claims that are incrementally differentiable but all sit on the same technical theme: residual water content as a gating parameter for a specific amorphous + HPMC-AS solid dispersion.

Claim set coverage map (based on your provided text)

Claim	Formulation elements required	Water limit (wt% of total composition)	Claim scope effect
1	Solid dispersion; 50 mg of amorphous Formula (I); HPMC-AS; water ≤ ~6%	≤ 6	Anchors independent scope; includes explicit 50 mg language
2-8	Same as claim 1	≤ 5; 4; 3.5; 3.4; 3; 2; 1	Narrows via moisture ceiling
9	Solid dispersion; amorphous Formula (I); HPMC-AS; water ≤ ~6%	≤ 6	Repeats concept without the “50 mg” element shown in claim 1
10-16	Same as claim 9	≤ 5; 4; 3.5; 3.4; 3; 2; 1	Narrows further
17	Solid dispersion plus one or more pharmaceutically acceptable carriers; includes amorphous Formula (I); HPMC-AS; water ≤ ~6%	≤ 6	Broadens to “additional carriers,” still gated by HPMC-AS and water limit
18-24	Same as claim 17	≤ 5; 4; 3.5; 3.4; 3; 2; 1	Moisture stair-steps

What do the “amorphous form of Formula (I)” and HPMC-AS requirements mean for infringement risk?

Amorphous form: functional state constraint

The claim requires that the compound “is present in amorphous form.” That is a material state limitation, not just a generic “solid.” In practice, this often becomes a definition-and-proof battleground:

If a competitor produces a dispersion where the active is partially crystalline (or re-crystallizes during processing/storage), they may argue non-infringement of the “amorphous form” element.
Conversely, if a competitor targets amorphous stabilization, they can fall directly into the claim if their characterization supports amorphous content consistent with the patent’s intended meaning.

HPMC-AS: excipient identity limitation

Requiring hydroxypropyl methyl cellulose acetate succinate is a specific polymer identity constraint. A common design-around lever is to use a different enteric/swellable polymer (or a different HPMC derivative without the acetate succinate substitution pattern). Under a strict literal reading of the provided claims, substitution away from HPMC-AS is the cleanest route to avoiding the “(b) hydroxypropyl methyl cellulose acetate succinate” limitation.

Water ceiling: process/manufacturing and stability risk

The water requirement is expressed as:

“water is present in the composition in an amount of no more than about X% by weight based on the total weight…”

That phrasing generally covers:

Residual moisture in the final dry solid dispersion at the time measured for composition.
Potentially moisture uptake during shelf life if accused products are tested in a state that exceeds the threshold at filing/launch time.

For infringement strategy, this is the element most likely to be supported by quantitative analytical methods (typical moisture analysis methods include Karl Fischer titration or loss-on-drying). For freedom-to-operate, the water ceiling makes the drying and packaging program a first-order risk driver.

How are the dependent claims structured: what water ranges (≤6 to ≤1 wt%) add?

The dependent ladder creates multiple infringement “targets”:

If an accused composition has water at (for example) 4.2 wt%, it would meet claim 1 (≤6%) and fail claims with ≤4% and below, while still potentially meeting other water-tier claims depending on the exact threshold.
If accused product moisture is variable batch-to-batch, the infringement exposure could map to the specific observed moisture distribution.

Practical claim mapping by water

Accused product water (approx.)	Likely claim coverage from the provided ladder
≤ 6% but > 5%	Claims 1 and 9 and 17; not claims tied to ≤5% or lower
≤ 5% but > 4%	Claims 2 and 10 and 18; also claims for ≥6 tier still covered
≤ 4% but > 3.5%	Claims 3 and 11 and 19
≤ 3.5% but > 3.4%	Claims 4 and 12 and 20
≤ 3.4% but > 3%	Claims 5 and 13 and 21
≤ 3% but > 2%	Claims 6 and 14 and 22
≤ 2% but > 1%	Claims 7 and 15 and 23
≤ 1%	Claims 8 and 16 and 24

What product configurations are explicitly included: 50 mg dose, carriers, and solid dispersion only?

Claim 1 includes a “50 mg” element

Claim 1 states: “a solid dispersion comprising: (a) 50 mg of the compound wherein the compound is present in amorphous form…”

That creates a potential limitation tied to the formulation unit dose or formulation basis. Claim 9 and claim 17 do not show the “50 mg” term in your excerpt. If the “50 mg” is interpreted as a per-unit-dose amount, it may limit claim 1 to specific dosage strengths, while the other independent-like repetitions (claims 9 and 17) could cover broader strength compositions.

Claim 17 explicitly permits additional carriers

Claim 17 expands beyond a “solid dispersion” alone:

It recites “a solid dispersion and one or more pharmaceutically acceptable carriers”
Yet it still requires the same polymer and moisture constraints inside the solid dispersion.

This prevents a straightforward argument that the formulation must be only solid dispersion with no other carriers. Competitors can include typical excipients (e.g., lubricants, disintegrants) as long as they maintain the amorphous state, HPMC-AS presence in the solid dispersion, and water cap.

What patent estate questions matter for U.S. 12,318,374: are there method patents, formulation variations, or only composition claims?

Based solely on the claims you provided, this patent reads as a composition-of-matter style formulation claim (solid dispersion in amorphous form, specified polymer, specified water range). No method steps are stated in the claims you pasted (no mixing, drying, milling, or thermal processing steps).

So the landscape implications are:

In litigation, infringement likely turns on finished product composition characterization rather than proof of the manufacturing procedure.
For design-around, the most direct levers are:
1. use a different polymer excipient than HPMC-AS,
2. deliver the active in a non-amorphous form, or
3. exceed the stated water cap (while accounting for whether “about X%” creates leeway).

How does U.S. 12,318,374 compare with common solid dispersion patent patterns in FDA/Orange Book strategies?

Typical competitive design-around patterns

For patents that lock on to “amorphous + specific polymer + residual moisture,” the usual competitive actions in the market are:

switch to a different polymer system (for example, different HPMC acetates, PVP/VA systems, HPMCAS variants, or non-cellulose polymer matrices),
adjust formulation to maintain amorphous state without the exact polymer identity,
change the moisture profile and packaging strategy, or
use different dispersion technologies (hot-melt extrusion versus spray drying) that yield different residual moisture outcomes, plus different solid-state distributions.

Potential relevance to FDA Section viii and device packaging

While the claims are not administrative, the water limit is tightly operational. Moisture management frequently becomes part of product-level controls that also appear in CMC dossiers. That links this patent’s practical enforcement to QC moisture specs and real-time moisture stability programs.

What would a Paragraph IV or biosimilar-style risk assessment look like for this patent?

Not biosimilar-relevant as drafted

This is framed as a pharmaceutical composition for oral delivery, not a biologic. So the “biosimilar” risk is not the typical analogue.

Paragraph IV for a small-molecule formulation

If a generic developer seeks to launch a competing oral drug product with the same active (the Formula (I) compound), risk exposure would typically concentrate on whether the generic:

achieves amorphous form of the same active in the same dispersion,
uses HPMC-AS in the solid dispersion,
and satisfies the residual water ≤ ~6% (or lower tiers).

Given the explicit excipient and moisture limits, a generic formulation that uses alternate carriers and/or alternate polymer systems could reduce literal infringement exposure. If it uses HPMC-AS and controls moisture to ≤ the same ceiling, exposure increases sharply.

What is the likely claim strength profile of U.S. 12,318,374?

On the provided record, the claim’s strength is tied to:

the uniqueness of HPMC-AS + amorphous solid dispersion for the specific Formula (I) compound,
the precision of the residual water parameter and how “about” is construed,
and whether the amorphous condition is reliably met in accused products.

Strength can be challenged by:

prior art showing similar amorphous solid dispersion compositions for the same compound with HPMC-AS,
prior art showing residual moisture control into the same numerical windows,
or prior art that anticipates the combination of features.

Because the claim is narrow in the polymer identity and residual water ceiling, it can be harder for a prior-art reference to anticipate the full combination unless it contains explicit moisture and polymer details.

Key takeaways

U.S. 12,318,374 is centered on an oral solid dispersion where Formula (I) is amorphous and the dispersion uses HPMC-AS, with residual water capped at ≤ ~6 wt% and dependent claims narrowing down to ≤ ~1 wt%.
The claims cover three structural buckets: (i) solid dispersion with an explicit “50 mg” element (claim 1), (ii) similar solid dispersion concept without the “50 mg” term (claim 9), and (iii) solid dispersion plus one or more pharmaceutically acceptable carriers (claim 17), all gated by the same amorphous + HPMC-AS + moisture ceilings.
Infringement is most likely tied to finished product testing for (a) amorphous state and (b) residual moisture, plus confirmation of HPMC-AS presence in the solid dispersion.
The strongest design-around lever implied by the text is substituting away from HPMC-AS; the next is changing solid-state (avoid “amorphous form”); the moisture ceiling is a third lever that shifts into CMC control and packaging/stability.
The claim set’s numerical moisture tiers create multi-level exposure depending on where an accused product’s measured water content falls within the ladder.

FAQs

1) How would a competitor design around a claim requiring HPMC-AS in a solid dispersion?
By replacing HPMC-AS with a different excipient system so the solid dispersion does not include “hydroxypropyl methyl cellulose acetate succinate,” while also maintaining the rest of the formulation constraints that avoid the same amorphous-state and moisture features.

2) If an accused product is amorphous at release but crystallizes in storage, does that avoid infringement?
It can, depending on what sample state is tested and whether the “present in amorphous form” limitation is evaluated at the time that corresponds to the asserted infringement scenario.

3) What matters more for claim coverage, manufacturing moisture control or packaged shelf-life moisture uptake?
Because the claim is framed as “water is present in the composition,” both the initial residual moisture and any later changes that bring the product above the cap can matter, depending on the product state used for testing.

4) Do the dependent claims create multiple infringement “hit points” for partial moisture compliance?
Yes. If an accused product is within the ≤6% tier but above a lower threshold, it may still fall under the higher-water claims while avoiding the tighter ones.

5) Are additional pharmaceutically acceptable carriers permitted?
Yes under claim 17, which explicitly requires “one or more pharmaceutically acceptable carriers” in addition to the solid dispersion, as long as the dispersion still contains amorphous Formula (I), HPMC-AS, and meets the water ceiling.

References

No patent bibliographic sources were provided (e.g., publication number, filing date, prosecution history, assignee, and actual USPTO claim set). The analysis above is based only on the claim text supplied by the user and does not include external citations.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	122354	⤷ Start Trial
Argentina	122355	⤷ Start Trial
Australia	2020417282	⤷ Start Trial
Australia	2020419197	⤷ Start Trial
Australia	2023241368	⤷ Start Trial
Australia	2023248048	⤷ Start Trial
Australia	2024227597	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 12,318,374

Which drugs does patent 12,318,374 protect, and when does it expire?

Summary for Patent: 12,318,374